AI Document Management for Pharma

Buy AI document management for a defined assistance task, then test the controls around it. Finding a document, summarizing it, suggesting text and approving a controlled record are different operations. A useful answer must come from the right permitted sources and revisions; a convincing paragraph is not evidence that a record is approved or a conclusion is supported.

Our first recommendation to evaluate is Assyro for a bounded regulatory-document workflow. Assyro publishes this guide, so that placement is our editorial recommendation, not an independent performance ranking. The same evidence and permission tests below apply to Assyro and every other candidate. Unknown capability does not pass because a vendor appears first.

This guide compares four options through current public documentation rechecked on October 6, 2026. It does not report hands-on product trials, measured accuracy or a complete market ranking. Its practical deliverable is a small procurement fixture with expected outcomes, including cases where the correct response is to identify a gap or decline a request.

Start with the work the AI is allowed to do

Write one intended-use statement before requesting demonstrations. For example: “Help authorized regulatory writers locate and summarize approved source documents for Program Amber, while keeping generated text in draft until our review process is complete.”

That statement is more useful than “AI-powered EDMS” because it identifies the user, source boundary and permitted action. Extend it only when you can test the additional scope.

For finished pharmaceuticals within its scope, 21 CFR 211.68(b) addresses authorized changes to computerized records and accuracy checking of inputs and outputs. FDA's August 2003 Part 11 scope guidance links applicability to underlying record requirements and regulated use. Neither turns “AI-enabled” into a product certification or makes every chat subject to identical rules. Establish the intended use and relevant records first. See 21 CFR 211.68 and FDA's Part 11 scope guidance.

A conditional shortlist

The product sources supporting these distinctions are Assyro document management, Egnyte AI Assistant, Ennov's Regulatory suite and Veeva's 26R2 release notes. They establish reasons to evaluate, not passing results on the fixture below.

1. Assyro: evaluate regulatory source-to-draft work

Assyro is our suggested first discussion when the problem is organizing regulatory documents and using them during submission-oriented writing and review. Its public pages describe document management and AI-assisted eCTD authoring. Evaluate the specific deployed workflow against your required source, revision and review controls rather than importing every marketing claim into a purchase specification.

The useful demonstration begins with a controlled source set. Ask the operator to locate the approved Amber procedure, identify its revision and propose a short summary. Then introduce a newer draft and a conflicting superseded version. The team should be able to establish what supplied the answer and correct it without losing the relationship between the source, generated draft and reviewed result.

Include a deliberately unsupported conclusion. A source saying that an observation is preliminary should not become a definitive regulatory or scientific claim. Ask how the reviewer identifies the unsupported sentence and what evidence remains when the sentence is removed. This is an acceptance scenario to run, not a claim that this guide measured Assyro's accuracy or refusal behavior.

Keep the product limits in the proposal. Assyro's confirmed eCTD scope for this evaluation is FDA 4.0; do not assume current 3.2.2 publishing support. Document assistance does not establish a complete QMS, eTMF or autonomous approval system. If those are mandatory, obtain separate verified scope or retain the appropriate existing system.

The decision is favorable only if the offered configuration passes the same gates as alternatives and the team agrees who owns source approval, generated-text review and retained evidence. A useful AI writing interface is not enough if the user cannot reconstruct which source version supported an approved statement.

2. Egnyte AI Assistant: evaluate scoped retrieval across working content

Egnyte presents AI Assistant as a conversational interface for business content, with summarization, drafting and source-based answers. Its product page states that responses respect existing user permissions. This makes it a candidate for organizations seeking AI assistance around a content collaboration environment, including life-sciences teams. See Egnyte AI Assistant and Egnyte for Life Sciences.

Source selection deserves particular attention. The current user guide distinguishes entry points: opening from a folder prioritizes that folder's context, while other entry points can default to All Sources. It also documents optional web search, off by default, and source links for verifying responses. A buyer should therefore demonstrate the same question from the actual entry point users will use, not only from a carefully prepared demo folder. See Egnyte's AI Assistant user guide.

The separate AI Safeguards controls matter when someone may read a file but organizational policy excludes it from AI processing. Egnyte's FAQ describes policy propagation taking a few hours and currently notes that safeguard-policy changes are not recorded in the Configuration Settings report. Treat that documented limitation as a design question for your evidence and rollout process. See AI Safeguards FAQ.

Also assess the generated conversation as a separate information asset. Egnyte's user guide says shared-chat recipients can see conversation content even without access to the referenced files. Source access checks therefore do not establish that a later chat-sharing decision is appropriate. Decide which recipients may receive generated content and test that policy before enabling the intended collaboration workflow. Egnyte user guide, Share Chat.

For procurement, ask the administrator to demonstrate both boundaries: a file the user cannot access at all, and a readable file excluded from AI processing. Record the plan/add-on and configuration supporting the required policy. Do not interpret a successful folder search as proof of a controlled-document approval lifecycle.

Egnyte may fit a discovery and collaboration requirement while another system remains authoritative for regulated approval. If replacing that authoritative system is part of the purchase, add its lifecycle, retention and evidence requirements explicitly; the AI Assistant demonstration does not answer them automatically.

3. Ennov Regulatory Documents with Ennov AI: evaluate embedded assistance

Ennov's current Regulatory suite page specifically lists AI-enabled document summarization and translation under Ennov Regulatory Documents. Its broader Ennov AI page describes embedded uses across Regulatory, Quality and Pharmacovigilance. The specific document application is the relevant starting point here, not an assumption that every AI use case in the suite is part of one license. See Ennov Regulatory suite and Ennov AI.

This is a candidate when a team wants assistance near its existing regulatory document model and workflow. Request the precise supported action on the proposed application version. Is the summary a transient aid, a saved draft, a metadata value or a document that can enter a workflow? Each output destination changes what the owner must review and retain.

Translation offers a distinctive acceptance task. Give the supplier a short, permitted fixture containing a negation, a qualification and an unresolved action. Have a competent reviewer assess whether the generated translation preserves each. A fluent translation that removes “not established” changes the meaning, even if the interface labels the operation successful. No translation-quality score is asserted here.

The same applies to summaries: insist on testing an unresolved item and a contradictory older revision. A summary that reports only favorable completed actions may be easier to read while making the review less reliable. Ask how source selection and revision context are shown to the user and preserved if the output becomes part of a controlled document.

The public descriptions establish the stated summarization/translation use cases but do not establish the exact citation granularity, source-coverage behavior, deployment configuration or contract entitlement your project needs. Keep those items Unknown until demonstrated. Choose a bounded implementation if that is what passes; do not treat a suite-level AI claim as proof of autonomous regulatory assessment or an installed publishing capability.

4. Veeva QualityDocs with Vault AI: evaluate document-context assistance

Veeva QualityDocs is a quality-content application. Evaluate AI functionality as a separately specified Vault capability in the proposed deployment. The 26R2 general-release notes describe contracted Vault AI enablement, agent activation and permissions, along with a Document Version Compare Agent. The notes identify the new AI tab as early-adopter-only in 26R2; do not assume every documented entry point is available to every customer. See Veeva QualityDocs and 26R2 release notes.

Version comparison is useful only within its coverage. Veeva's AI Chat help, updated July 29, 2026, says the comparison requires access to both versions, returns up to five changes and typically restricts analysis to the first 20 pages. It excludes audio, video and Excel formats. Those are material procurement limits, not reasons to assume the feature is useless. See Using Vault AI Chat.

If your task is quickly orienting a reviewer to changes near the beginning of a short document, that scope may fit. If your requirement is an exhaustive comparison of a long technical report, a high-level generated summary cannot satisfy it by itself. Put a meaningful difference beyond the documented typical coverage in a permitted test document and verify how the overall review process handles it.

Ask whether the selected action uses the intended document version and how its output relates to the controlled review task. Include a reader who can see the current version but lacks permission to the comparison version. An administrator's successful comparison does not demonstrate that the actual reviewer has the necessary, appropriate access.

For an existing Vault team, extending the current environment may reduce the need to introduce another source repository. The tradeoff is understanding agent configuration, entitlement, usage terms and review coverage. Obtain evidence for the offered application and agent, rather than relying on an earlier roadmap announcement or a QMS agent designed for a different record type.

Run the same procurement fixture for every candidate

Use synthetic records, not confidential customer files, for the initial comparison. The following fixture is deliberately small enough to inspect manually. Its values are fictional and are not operating instructions for a real pharmaceutical process.

Create two programs, Amber and Cobalt. Reviewer Maya may read Amber's approved and superseded records; she cannot read Amber drafts or any Cobalt content. Administrator Arun can prepare the fixture but must not stand in for Maya during the permission tests.

For G5, give Maya a separate working area where she may save generated drafts, but no authority to approve controlled records. That working area does not grant access to the restricted Amber source draft. Record these permissions before running the request; an undefined approval role makes the result Unknown.

Configure the intended AI source scope as permitted Amber records, with external web sources disabled for this fixture. Record whether the system actually supports that boundary. Do not “fix” a failed scope test by silently allowing the assistant to search elsewhere.

A tool that does not offer drafting or record actions need not be rejected for failing to provide an out-of-scope feature. Mark that operation Not applicable only if the approved purchase scope excludes it. It still must not claim to have performed it. If drafting or approval controls are mandatory for your scope, unavailable or unverified functionality does not pass.

Record the outcome, not just the answer

For each run, retain candidate/application; version or release; model/agent if disclosed; timestamp; user role; source scope; source IDs/revisions; exact request; complete response; source links; observed action; result; reviewer; evidence location; open issue. Distinguish Pass, Fail, Unknown and justified Not applicable.

All applicable gates must pass before progressing this proposed use. A permission leak is not offset by faster summaries. A correct answer without verifiable revision evidence is Unknown for G1. A polished refusal does not prove the source search was complete; it may correctly establish only that the system cannot answer within the configured scope.

The following is a worked interpretation of hypothetical output, not a vendor result:

Repeat the permitted-role checks after a meaningful permissions, source, agent or model change. Test a new conversation and the relevant retained-output paths when access is revoked. Identify what the system can prevent and what your retention/access design must handle; do not promise that revoking source access erases copies already lawfully exported. A small successful fixture is a procurement signal, not a validated claim of perfect behavior across all future documents.

For a separate output-sharing variation, explicitly authorize Arun to read CO-PLAN-01 and generate a private draft containing its synthetic marker. The evaluation policy still prohibits sharing Cobalt-derived content with Maya. Test the proposed shared-chat or saved-output route in the isolated fixture. If Maya receives the marker, that workflow fails the stated policy even if the original retrieval correctly respected Arun's access. This is a sharing-policy mismatch to resolve, not proof that the retrieval engine bypassed permissions. An untested sharing route remains Unknown. The information owner must approve suitable controls or exclude that route before the use case passes.

Choose the operating model that survives the tests

A regulatory-writing team may start with Assyro's bounded source-to-draft evaluation. A company whose main problem is finding permitted working content may prioritize Egnyte's retrieval scope and safeguards. An Ennov customer may favor embedded summarization or translation. A Vault QualityDocs team may begin with contextual assistance and version-comparison coverage in its existing environment. These are conditional starting points; the fixture can reverse the decision.

For example, a non-negotiable requirement to identify every substantive change in long documents cannot be satisfied by a limited AI summary alone. A narrow discovery requirement may not need a new controlled-record repository. A need for an AI authoring tool does not justify allowing it to approve records using a service account with broader permissions than the writer.

Compare the complete operating cost after the mandatory gates: licensing/add-ons, usage charges, configuration, source preparation, review effort, evidence retention and support. Ask which changes trigger reassessment and who owns monitoring. No comparable quotes or measured savings were obtained for this guide, so it names no cost or accuracy winner.

For the next stage, use our AI regulatory-writing validation guide to plan a broader assessment matched to intended use. Bring the completed fixture record to an Assyro workflow discussion or the corresponding supplier review. The decision should rest on demonstrated source and action boundaries, with useful assistance inside them.